WHO ICTRP trial
I8D-MC-AZET
JPRN-jRCT2080223444 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2080223444 |
|---|---|
| Public title | I8D-MC-AZET |
| Scientific title | A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia (The DAYBREAK Study) |
| Primary sponsor | Eli Lilly Japan K.K. |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Japan;Asia except Japan;North America;Europe |
| Conditions | Alzheimer's Disease Dementia |
| Interventions | investigational material(s) Generic name etc : LY3314814 INN of investigational material : Lanabecestat Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administration for Investigational material… |
| Registration date | Jan 23, 2017 |
| Target size | 1899 |
| Secondary IDs | NCT02783573;JapicCTI-173499 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: